New cancer drug PM14 enters human testing for advanced tumors

NCT ID NCT05076396

Completed Disease control Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first step to see if PM14 is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PM14 (a new anti-cancer drug given by IV infusion)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety and dosing, not yet proving effectiveness. The drug may cause side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Clinica Universidad de Navarra

Madrid, Madrid, 28027, Spain
Gustave Roussy

Villejuif, París, 94805, France
Hospital General Universitario Gregorio Marañón

Madrid, Madrid, 28007, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Catalonia, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario Fundación Jiménez Díaz

Madrid, Madrid, 28040, Spain
Hospital Universitario Madrid Sanchinarro

Madrid, Madrid, 28050, Spain
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.